
These records are from CDER's historical file of information previously disclosed under the Freedom of Information Act (FOIA) for this drug approval and are being posted as is. They have not been previously posted on Drugs@FDA because of the quality (e.g., readability) of some of the records. The documents were redacted before amendments to FOIA required that the volume of redacted information be identified and/or the FOIA exemption be cited. These are the best available copies.





NOV 19-123

Upsher-Smith Leboratories, Inc. Attention: Mr. Fred 1. Webling 14905 22rd Avenue Verth Minnekpolis, Mi 55441

Dear hr. Wehlipo:

-:5

We also acknowledge receipt of your arendwent dated Novamber 27, 1985.

We have completed the review of this application including the submitted draft lakeling and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed draft labeling. Accordingly, the application is approved. Prior to marketing, however, please submit thelive copies of the final prime. labeling that are identical to the graft. Please individually mount seven of the copies on heavy weight paper or similar material.

In the near future, we plan to requise rovision of current potassiar clionic Tabeling that incorporates entoscopy study findings as well as content are format specifications. Is do expect your cooperation in saling changes when our internal deliberations have been completed.

perieting of the any before the final printed lateling is subsitted to fur-

Should additional information relating to the safety and effectiveness of the drug becaus available prior to our receipt of the final printed labeling, ______ revision of that labeling tay be required.

In addition, please submit, in deplicate, the edvertising casy that you latence to use in your proposed introductory promotionel and advertising compaign. Please submit one capy to this division and the second, along with a copy of the package invert directly to:

> Stylston of Grug Advertising and LuneTing, MFX-740 Aug. 166-64 AGOD Fishers Lane Recevilie, Peryland 20867

Flease sublit one samiet photoge of the drug when it is available.

set forth under 21 LFR 314.80 and 314.71.

If you have any questions, please contact:

Fr. Peter Barille Consumer Safety Officer (301) 443-4730

Sincerely yours,

Exympted J. Lipichy, M.V. Acting Hirecton Livision of Carolo-Renal Drug Products Uffice of Grug Research and Pevic Center for Drugs and Hologics

A

	Original MA	
	HEN-24C (with labeling)	
_	HFY-237 (with labeling)	
	NFi-110/Aven111a/12/18/C5	
		<u></u>
	R/D 1mit: Withosenthal/12/20/05	
	Globason for Chesnick/12/24/85	
	Wier yemstern/12/24/65	



DIVISION OF CARDIO-RENAL DRUG PRODUCTS DIVISION DIRECTOR'S REVIEW

NDA: 19-123

Sponsor: Upsher-Smith Laboratories, Inc. 14905 23rd Ávenue North Minneapolis, MN 55441

Product: Trade Name, Klor-Con (8 and 10 mEq dosage forms) Generic Name, Sustained release, wax-matrix, oral, solid dosage form of KCl

Date of Submission: August 16, 1983, resubmitted August 16, 1984, nonapprovable letter issued December 1984, resubmitted.

Date of Review: April 15, 1986

After some time, this NDA is now approvable. The major problem related to previous non-approvability was the bioavailability study originally submitted by Upsher-Smith. The data have been re-analyzed and submitted on November 27, 1985. This submission and its data make the necessity of consulting our biostatisticians (which was thought to be necessary at our mouting with Upsher-Smith on November 6, 1985) unnecessary and the problems discussed in the entire meeting of November 6, 1985 are essentially moot.

As it now stands, there is no statement by the Division of Biopharmaceutics that the Upsher-Smith bioavailability study is acceptable. I have not referred the November 6, 1985 submission to the Division of Biopharmaceutics and this review constitutes my own review of that study which I find adequate, based on the November 6, 1985 analysis.

Prior to reviewing the study, a brief statement of my review regarding the purposes of a bioavailability study for a KC1 product is in order.

At present, no one has devised a better method for assessing bioavailability than to administer the KCl product orally and to concomitantly measure the appearance of K ion in the urine. Orally administered potassium enters a large body pool when and if absorbed and the K which comes out in the urine may or may not represent any of the actual K administered orally. At the limit, all of the K administered orally could be absorbed but none come out in the urine.

Consequently, even though studies try to establish steady-state with respect to intake of dietary potassium and try to ensure adequate urine volume so that NDA 19-123



The mean 24-hour cumulative excretion of potassium is not statistically, significantly different between any of the treatment. The sponsors do not have a power calculation, and I did not perform one, so I cannot say what confidence one can have that if there had been a difference one could have, detected the difference.

However, the preamble to this review asserts that bioequivalence is not required of oral, solid, dosage forms of KCl. One cannot determine rate and extent of absorption from experiments of this type, so an absolute bioequivalence statement cannot be achieved; even if sufficient power is present to directly compare any measurements made. The various KCl formulations are not generically equivalent and are not (in fact should not) be dispensed interchangeably. So not being able to make a firm statement with respect to "extent," in its loosest sense, in no detriment with respect to decisions regarding approvability.

My conclusion then is that the Klor-Con tablets are bioavailable and from that vantage point meet that standard for approvability. The studies were reasonably designed, poorly conducted and reluctantly analyzed, but the result, with respect to bioavailability, is sufficient to form a basis for approval.

The time course of potassium excretion is shown in Figure 1. The visually apparent difference between Klor-Con-102 and all sustained release formulations (between 0 and 6 hours) was statistically significant at a p value of 0.0027. This reasonably establishes that the Klor-Con tablets exhibit sustained release properties in vivo and consequently can be labelled as a sustained release formulation.

Summary

I see no outstanding issues that need resolution. The edited package insert is reasonable. It is to be updated sometime soon and the approval letter should so indicate. This memo and the appended disclosable reviews constitute the SBA.

Raymond J. LINICKY. M.D.

Division Director

cc: ****dwig:****** #FN-110 #FN-110/CS0

HFM-110/RLipicky ef/4/28/86/#0508g

c

NDA 19-123



bad feature of the study. All 24 subjects completed the study and values for all 24 subjects were used for all calculations.

The study lasted a total of 19 days during which a planned diet consisting of about 50 mEq potassium and 3000 ml of liquid (not enough) were ingested per day. A 4-day lead in period was planned (the 5th day being the first dosing day) and dosing occurred every 5th day thereafter. Fractionated urine collections obtained on the 4th day were used to correct for baseline potassium excretion. If the baseline urinary potassium, at any interval, was greater than that on a dosing day (which would have been a negative value when subtracted) the value for the difference was set to 0.

There were 768 estimates of urinary potassium, 197 values of 0 were assigned to the baseline substracted values, essentially about a 25% incidence of indeterminate values. Two subjects for two treatment periods each had 0 values assigned for all collections and one subject had 0 values assigned for one treatment for all collections. Seventy-three (almost 40%) of missing values were were first 2 (0-1 hour and 1-2 hour) collections, the reminder were scattered between the 3rd (2-3 hour) and 7th samples (8-12 hour) with only 5 out of 96 values being 0 in the last collection interval (12-24 hour).

The baseline corrected mean (+ SEM) cumulative urinary excretion of potassijum, 0 to 24 hours is given in the following table.

Figure 1

	Mean 0-24 hour potassium	
Drug	excretion	SEM
Klor-Con 8 BEq	21,71 #Eq	
Klor-Con 10 mEq	24.82 mEq	2.15
Slow-K	21.87 mEq	2.08
Klor-10%	23.05 mEq	

The probabilities that the mean baseline subtracted, cumulative 24-hour potassium excretion was 0 were 0.0001, 0.0001, 0.0001 for Klor-Con 8 mEq, Klor-Con 10 mEq, Slow-K and Klor-10%, respectively. Consequently, one can conclude with reasonable certainty that some potassium was absorbed from each of the potassium formulations and consequently Klor-Con 8 mEq and Klor-Con 10 mEq are bioavailable.

The potential error of assuming 0 values, when the baseline was greater than on drug day (i.e., would have vialided a negative value) are inconsequential to the major conclusion. Not only does K come out of the wax matrix when the tablet is placed in water in a rotating bottle, it also does so in vivo.

3

MDA 19-123

urine collections can be made at short intervals (to measure rates of excretion as best as possible), under the best of conditions a KCl bioavailability study cannot measure the rate and extent of absorption. These are the two estimates one desires of a bioavailability study and are the two parameters that judgments with respect to bioequivalence are made from; a comparison of area under the curve is generally not suitable for a bioequivalence determination.

So then, what can one conclude from a bioavailability study of orally administered KCl? The answers seem straight forward enough.

1) One can conclude that some of the administered dose is absorbed even though one cannot explicitly conclude how much of the administered dose was absorbed. By comparing the urinary excretion between several formulations, including a solution of KCl, one can hope to make some crude relative comparisons but a bioequivalence statement cannot be made.

2) By comparing the time of peak urinary excretion rates (at midcollection point) occurring after each formulation tested to the time of peak urfmary excretion rates, occurring after KCl in solution, one can determine that the formulation in vivo has slow release characteristics. This deduction has unverifiable assumptions and even if in vivo slow release is not locumented, the only consequence is that one could not make a slow release claim.

With respect to rates of excretion, if one cannot obtain voided samples of urine at close enough intervals, the estimate of rate will be poor. That is, if the rate estimates were based upon a single 24-hour collection interval and similar amounts were excreted over that interval, all rate estimates would be identical even though enormous differences in rates may have been present early in the 24-hour period.


With respect to the Upsher-Smith study, it is known (from an on-site inspection as well as from evaluation of the data) that care was not taken to adequately hydrate the subjects and there were missing values for urinary concentrations of K for many subjects, especially at early collections (0 to 1-hour samples because the subjects were not able to void at the commanded times). In general, the study did not seem well run, however, 1 believe conclusions can be drawn and the data support approval.

The <u>Study</u>

Ivanty-four normal, male volunteers were involved in four way, planned sequence, cross-over trial. Each of the four treatments involved oral administration of 40 mEq KCl (' tablets of the 8 mEq Klor-Con, 4 tablets of the 10 mEq Klor-Con, 5 tablets of Slow-K and 30 ml of a 10% solution of KCl as upaker-Swith's Xlor-10%), which is a relatively low dose and is an additional



2





Nexue was 10.00 CON[®] Extended-relates tablets are film control (out entrols cont to containing 600 mg (operation) to 8 mEs) or 750 mg (operatoriset to 8 Reserves chipsign is an analysic of the second antender has an analysic of the control of the second second antender transform to the second هو منبا nt 10 10 mEn) <u>.</u> (2 and its melecular weight in 74 55. This set patients in applicance formation intended to provide a controlled spinor of peterstame have the metric to mini-pet-in Medievel of producing high taraffect concentrations or patienties within 9 interlational least. The implement reasons is not about an any be even; ACT and its malacule فلأ بتثلك سيتيداك ni ani ugy be overkad inat in the stat

in Agendiarts: Caster of, BBC Yalam Ha. 18 (alexainen tatus ». - 786C Mas Ha. 1 (alexanars tatu), ty-propyl mellyfediatets 2978, megnetine staareta, priyatydes:- ----eni 3358, proyekna gigest, syntysia ide, and allow ingo

LINES, PRODUCTION

n, Franzenserezy. genera sen et tre prezistet interzetteter cetter af mont høyt tiggegt. Petugstangiget gerrickade en treaster nint physiological processes, including the montenence of interzetteter yoticity, the transposed of serve 14. The contenction of contex, cholosof, and streacts maycle and the maintenance of memory genes type; you B و او ----

Peterseum depteters anny accur deservar the rate of potentians have through a Bister interferent fract an Coats the rate of patentians interior. Such deptetion as ngih fintal contraints and/or in n î nily devalues shouly as a co Recorders, diabatic hotescid (hits initial net inscission) the rate of palaosisme interior. Such depiction aroundy develops shouly as a con-singe of prolonged thereby with and disording, primary or spranghay hyperchlosenerstein, disbatic testescide-tensors disortion, or interforgents replacement of patientics in patients on prolonged permisers maintains taking digitation due to flame causes is smallly accompasied by a cases without differency of observations, for-factors digitation due to flame causes is smally accompasied by a cases without additionaty of observations, for-factors digitation due to flame causes is smally accompasied by a cases without additionaty of observations, for-mation digitation due to flame causes, is caused, according to a second state of the discretion, and on ad-minant distance and matching accepts boots), provident to causes in the discretion part of ad-second distance and accepts boots). ł and cross factor paralysis and/or objected ability to concentrate serve.

Phasener depiction associated with mothetic allocation is more provide the fundamental causes of R-2 Collectory valences possible and administering supplemental polassium chards, in the turn of high polassium had or palassium chards administering supplemental polassium chards, in the turn of high

R une circumiteres (e.g. putert: with read labels: acidanis) polassions deploten may be associated with Initialic acidents and hyperclassesia. In such policies privation replacement should be accomplished with Maxwen salls offer then the clientic, such as polations bicarbonals, polassons circle, or privations

DECANSE OF REPORTS OF RITESTINAL AND GASTRIC LECERATION AND RECEDING WITH EXTENDED RELFASE POTABSION CRUSHOE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUGE TO TAKE LIQUID OR EFFERICEDCENT POTASSION PREP-ANARIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREP-

alic ma in pallaria ville legarizzania ville a villenet matakalic pluzizzio, in dipense internazione a ville legarizzania familia postala pantjone.

execution of personant contents and destroy into the procession is includents in the following re-s: Patients massiving digitalis and disastics for comparison teach failure, hepetic contents with speares, is of addetionant excess with normal spear function, patientsian being anytompatys, and contain dor-700 status of skinst ant states.

3. The sate of polynomials in polynomials includely districts for meaninglicated expected to provide the statement of the polynomial statem

Polacelore segularizate are controledicated in patients web hypertationing since a further increase in spec folgeion concentration in such patients can peoplete carding arreat. Hypertations may complete arry of th Inning conditions: absent annot labori, systems anisosis park as distants: andreas, sovie displayable or anism 19 March Inning conditions are separate toring, apternal anishesis park as distants: andreas arry of a property 19 March Inning conditions are separate toring. Apternal and the second f nter, transport or guilarit lic (e.g., spirate

. You make petinden stänik populan kon peting A anglagnat semjasaika das ta an arkupat ist akim, i ang ing si sisaniya nagatris salina pi inte i

Mentidenege house of partonics any planets are configurated in any patients in when there is cause in Start or shing in White partons through the perturbation inst. In these initiaties, periodicies supplement, and should be with a liquid paymenting.

2 Land 1

÷.

F.


1


unite Mathenia: El patients with Inputient anclanitation for deputting patientians, the patients time of patients Is an produce hyperbolicate and conflict proof. This occurs angle commutiy in particular given patientian by minaments state but they also more for patients great patients and . Patientially to al hyperbolicate care the inter فيسرعه والاحد والجيدة

The use of patronium suffic in patronis with characteristic strait domain, or any other condition which impairs Response according, requires particularly candid meaking of the source patronium concentration and appro-inte descent administry. in desegn adje . . .

energia and finanziae dening disention: Hypikalania thanki ont in instant by the tenetationst advances patember with parts patember sparing disents (# 5, spinnatesian, virus, ar andonia), since the patember spinisteric different spinis can produce server hypotestania تتغيل intering part

• - .





Division of Cardio-Renal Drug Products Medical Officer's Review

NDA: 19-123

Review Date: July 5, 1984

Sponsor: Upsher - Smith Laboratories, Inc. 14905 23rd Avenue North Minneapolis, MN 55441

1. General Information

- (a) <u>Drug Name</u>: Klor-Con (potassium chloride in 8 mEq and 10 mEq film coated, wax matrix, controlled release oral tablets)
- (b) <u>Proposed Indications</u>: The customary indications for oral potassium supplements, including the treatment of hypokalemia, digitalis intoxication and hypokalemic periodic paralysis, and the prevention of hypokalemia in selected patients.

2. Manufacturing Controls

Refer to Chemistry Review.

3. Pharmacology

A. Pharmacokinetics

The sponsor has submitted one human bioavailability study (Vol. 1.2, p 10.0000). This is a four way, planned sequence, cross-over trial in 24 normal male subjects, comparing the bioavailability of 40 mEq doses of Klor-Con 8 mEq, Klor-fon 10 mEq, Slow-K, and 10% KCl solution. Sujects were confined and maintained on a diet containing 50 mEq potassium and 3,000 ml of liquid per day. Bioavailability was assessed by urinary potassium excretion over the 72 hours after administration of each of the four test drugs. The sponsor has reported and analyzed data for mean urinary K excretion for each test drug with respect to the entire 72 hour period and various fractions thereof. Adjustments were made for the contribution of dietary potassium to potassium excretion. After these adjustments, there were no significant differences between any of the four preparations during any of the intervals up to 72 hours. For more detailed information, refer to the Biopharmaceutics review.

Page 2 - NDA 19-123

B. Toxicology

The sponsor submitted one study of animal toxicology in cynomolgus monkeys. Four parallel groups of monkeys, each containing three males and three females, received Klor-Con 10 mEq, Lilly Enseals, Slow-K, or empty gelatin capsules. KCI was administered at a dose of 3000 mg. The results of this study are presented in the table below, taken from the 'Pharmacology review. They show large bowel lesions in the Enseals group only, and an acceptable level of small bowel and gastric toxicity for Klor-Con. The study is acceptable. For more detailed information, refer to the Pharmacology review.

 Form, Tabs	Dosnge,	Tabs Ma	Dosage/Jay	Diarrhea 4 soft stool	Stomach	ESIONS S-J	L-I .	
Control	2	2			0/6	0/6	0/6	· ···· · · · ····
Lilly Engals 13m Eq	5 2	1	3000 mg 508 to 1000 m	2/4 19/kg	1/6 h 1/6 U	1/6 h (882mg/kg)	1/6 U 1/6 e	
Slov-K Ør Eg	3	2	3000 mg 508 to 1000 m	4/4 Ig/kg	1/6 h 3/6 U			. •
Kier Con 10m Eq	2	2	3000 mg 508 to 1000 m	2/4 Ig/kg	1/6 U (M 769 mg/kg	<pre>1/6 h) (11eocecal valve).</pre>)	

Table I Results of Monkey GI Irritation Study

U = elceration; e = erosion; h = hemorrhage

4. Clinical Studies

Ŧ.

The sponsor submitted the results of two clinical studies, a multicenter use trial and a comparative upper GI toxicity trial.

<u>The Use Trial (Vol.1.2-1.4)</u>

Two investigators were involved in this trial. One was Jack Blackshear, M.D. of Little Rock, Arkansas, and Jules Kann, M.D. of Pittsburg, PA. Each investigator used the same protocol, but the results were presented separately.

)

Page 3 - NDA 19-123

The design of the trial was simple and straightforward. The study population consisted of hypertensive adults receiving antihypertensive therapy and potassium supplementation at any dose up to 80 mEq/day. No exclusion criteria were listed. Before starting study drug, each patient had a CBC, z UA, a standard automated chemistry panel, a stool for occult blood, and an ECG. Patients were then openly switched from their prior potassium replacement (Slow-K in most cases) to an approximately equivalent dose of Klor-Con 10 mEq, given in two divided doses. Serum potassium and stool for occult blood were checked at 2, 4 and 8 weeks (the end of the study). Patients were interrogated concerning adverse reactions at each of the three repeat visits. Patients also had a physical exam at the end of the study.

Forty patients enrolled in Dr. Blackshear's arm of the study. Each patient had been taking three 8 mEq Slow-K tablets. All of these patients were started on Klor-Con at a dose of 20 mEq/day. Twenty-two patients remained on this dose throughout the entire eight week trial, while 12 had their dose increased to 30 mEq/day, and another six had an increase to 40 mEq/day.

No patient reported any side effects, and all of the 160 stools for occult blood in this study were negative.

The mean serum potassium level for the 40 patients in this study rose from 3.7 mEq/liter at baseline (ronge, 2.7 to 4.8 mEq/L) to 3.9 mEq/liter at eight weeks (ronge, 2.8 to 4.9 mEq/L). At baseline, 14 patients had serum potassium levels below 3.5 mEq/liter, compared to four patients at day 55.

In Dr. Kann's arm of the study, there were 22 patients. These patients were somewhat more variable in their prestudy potassium dosage, which ranged from 4 to 60 mEq/day. Then patients were switched to Klor-Con, the dose they were given was in most cases slightly higher than the dose prior to the trial, in contrast to Dr. Blackshear's study. In which the opposite was true.

No patient in Dr. Kann's study had any adverse reactions. However, while all of the patients had negative stools for accult blood at baseline, three of the 22 patients had one subsequent trace positive stool for occult blood, while one other patient had two subsequent trace positive stools for occult blood. None of these patients had any symptoms.

Page 4 - Mits 19-123

Relevant data for those four patients is presented in Table 2 below:

)

Table 2 Patients with Positive Stools

<u>Pt Age</u>	<u>Sex</u>	KCI Dose in MEQ/day	f of Pos. Stools	Baseline Hct	Final Hct
59	F	20	2	46.0	43.9
56	F	20	7	42.3	40.8
56	F	20	1	46.1	45.0
43	F	30	Ĩ	44.2	44.5

HC: = hema: ocr 1t

In this arm of the study, serum potassiums at baseline ranged from 3.1 to 5.7 mEq/liter, with a mean of 3.5. At the end of the study, they ganged from 3.1 to 5.6, with a mean of 3.87. Serum potassium levels less than 3.5 mEq/liter were present in 13 out of 22 patients at baseline but only in 3 of 22 patients at the end of the study.

Reviewer's Note: This appears to be an adequate use study both in terms of the limited amount of safety data and efficacy data presented.

Uppl <u>GI Textcity Study (Vol. 2.1)</u>

The investigator for this trial was Kenneth Krantz, M.D., Ph.D., of Kansas City, Missouri.

This was a randomized, three-way, parallel-group study in subjects confined over II days. The study was open Tabel, but blindly evaluated.

Subjects were healthy adult males between the ages of 18 and 45 with normal CBC, wrinelysis, stool for occult blood, EKG and routine blood chemistry. All subjects had normal physical exams and no history of 67 discase. In addition, all subjects were required to have normal 8.1 mucose on a screening endoscopy performed immediately prior to entry into the study. It is not clear how many patients were screened in order to provide the 30 study subjects. Page 5 - NDA 19-123



4

Subjects were confined and placed on a hospital dist with no red meat, turnips, or horseradish. High fiber foods were included to provide bulk to facilitate stool collection for daily stools for occult blood.

On the day after the screening endoscopy, all study subjects were begun on glycopyrrolate 2 mg tid. In addition, patients were randomly allocated to receive Klor-Con 10 mEq tablets (70 mEq daily), Slow-K 8 mEq tablets (72 mEq daily), or placabo tablets (6 tablets daily). Study medications were taken three times daily <u>after</u> meals for 7 days. No concomitant medications were allowed.

On the day after study medications were discontinued, patients were re-endoscoped. All endoscopies in this study were performed blindly by a single endoscopist. The following scoring system was used: 0 = no lesions; 1 = one mucosal hemorrhage; 2 = more than one mucosal hemorrhage. Scores as high as 6 were to be given for more severe lesions, but no subject received a lesion score greater than 2. Erythema was noted, but not assigned on a numerical value. The esophagus, stomech, and duodenum were each graded, and their scores were reported.

The three study groups were comparable in terms of age, weight, and vital signs. All patients completed the study. The initial endoscopy for all patients was normal.

The results of the final endscopy are summerized in Table 3. No petient had graduable locions in more than one anatomic region, and only the most severe locion score is reported for any patient.

			· _	· · · · · · · · ·
	_		BeeuTte	
	<u></u>	Hoscopy Study		· · · · · · · · · · · · · · · · · · ·
				•
	Fraction with	f with	# with	/ with
Drug.	Lesions	SP WITH BEEN	Grade 1	Grade Z
		•		
Klor-Con	4/10		<u> </u>	<u>v</u>
STON-K	1/10	0	ł	9
		<u>· ·</u> · ·- -		<u> </u>
	······································	<u> </u>		····· - · · · · · · · · · · · · · · · ·
			-	· · · · · · ·
				- ··
		·		
		•		
- •				
				- ···· · · · · · · · · · · · · · · · ·
· · · ·				· · · · · · · · · · · · · · · · · · ·
	<u> </u>			
· ··· ··· ··· ··· ··· ··· ··· ··· ···				

Page 6 - MDA 19-123

The sponsor stated that none of the lesions were believed to be clinically significant, and all could be considered as chance events in normal subjects.

There were no positive stools for occult blood in the study.

In the ten patients taking Klor-Con, four complained of abdominal pain or vomiting at some time during the period of drug administration. In the Slow-K group, these symptoms were reported by three patients. In the placebo group, four patients reported one or more of these symptoms. In no patient were these symptoms considered serious.

Reviewer's Note: The study is acceptable. The lack of serious Testons in persons receiving Klor-Con and Slow-K is consistent with limited data from other gastroscopy studies suggesting that administration of wax matrix products with or after meals is associated with a comparatively low incidence of UGI erosions and ulceps. The finding of grade 2 lesions in two placebo subjects suggests that the (blinded) endoscopist did not systematically grossly under-read the endoscopic evaluations. These results, together with the findings of the monkey study and the use trial, suggest that the UGI irritent potential of Klor-Con is acceptable.

Labeling Review

A L H.

CARE THERE AND A DEPARTMENT OF THE


÷

The proposed labeling for Klor-Con is generally consistent with the labeling for Slow-K and other solid dose KCI products.

However, the paragraph on bioavailability (found on page 04 - 0021 of Vol 1.1) is somewhat ambiguous, and should be reworded. The second sentence of that paragraph should read "there were no significant differences in the cumulative amount of potassium excreted over periods of 24, 48, or 72 hours between 40 mEq doses of Klor-Con 8 mEq, Klor-Con 10 mEq. 102 potassium chloride solution, and a reference 8 mEq slow release tablet."

Conclusion and Recommendations

The NDA is approvable. A minor change in labeling is discussed under the previous heading.



Division of Cardio-Renal Drug Products CHEMIST REVIEW NUMBER TWO

> Completed: November 28, 1984 (Twenty days since last emendment)

E a

A. 1. NDA 19-123 ORIGINAL NEW DRUG APPLICATON-AS AMENDED

Applicant: Ellis Pharmaceutical Consulting, Inc. 913 State Road Princeton, New Jersey 00540-1484 Telephone: (609) 924-7212 for

> Upsher- Smith Laboratories, Inc. 14904 23rd Avenue North Minneapolis, MN 55441 Telephone: (612) 472-4412 Fred J. Wehling Director of Regulatory Affairs

2. PRODUCT NAMES:

.

<u>Proprietary:</u> KLOR-CON 10 mEq (750 mg) (Potassium Chloride) Slow

KLOR-CON 8 mEq (600 mg) (Potassium Chloride) Slow Release Tablets

Non-proprietary: Potassium Chloride 750 mg per tablet Potassium Chloride 600 mg per tablet


USAN: Potassium Chloride

<u>Compendium</u>: USP XX (1980), Page 642, and 5th Supplement page 1065. [N.B. USP XX1 is not yet offical].

DOSAGE FORM: Extended-release tablet. Oral route. Rx N.B. These tablets are not enteric coated but they are film coated to control the release of potassium ion from the matrix.

. PHARMA COLOGICAL CATEGORY: Hypertension in edults requiring

controlled release potassium supplement in order to maintain normal serum K + level.



<u>/ 4</u> 1 1

Ì

NDA 19-123

Klor-Con 🔸

Upsher-Smith Labs

Review and Evaluation of Pharmacology and Toxicology Data Original Summary

<u>Category</u>: Slow-release potassium chloride preparation for potassium supplementation

<u>Composition</u>: film-coated tablet containing 600 mg (BmEq) or 750 mg (10 mEq) of potassium chloride in an inert, non-absorbable watrix

Indication: for therapeutic use in patients with hypokalemia with or without metabolic alkalosis and for prevention of potassium depletion; usual dosage is in the range of 20 mEq (1500 mg) per day for hypokalemia and 40-100 mEq (3000 - 7500 mg) per day for treatment of potassium depletion

Related IND:

(

Related NDA: 17-476; Slow-K (Ciba-Geigy)

.)

Summary and Evaluation

Sponsor has submitted an NDA for a slow-release potassium chloride product similar pharmacokinetically to the wax matrix products such as Slow-K, but with a non-eroding polymeric film coating which controls the release of the potassium rather than a sugar-coated slowly dissolving wax matrix formulation. A gastrointestinal toxicity study of Klor-Con was conducted in Cynomolgus monkeys for 5 days. This study was previously reported under IND 19,251 and evaluated by Pharmacology Review dated 8/11/82. In this study, Klor-Con was compared to Slow-K and an enteric-coated product (Enseals). The dose for each was 3000 mg/day (600-1000 mg/kg) given in 2 divided doses. A control group was also included. The results for GI toxicity can be seen below:

Table of Microscopic Pathology

	Stomach	Small Intestine	Large Intestine	
Contro]	0/5	0/6		
	1 /6- H	1/6-H	1/6-0	
Enses1s	1/6-U		1/6-E	
	1/6-H			
Stow-K	1/6-H 3/6-U	· ·		
K1or-Con	<u> </u>	<u>1/6-H</u>	· ···- ··· ··· · ·	
· · · · · · · · · · · · · · · · · · ·				_
	<u> </u>		· · · · · · · · · · · · · · · · · · ·	
	-			-

NDA 19-123

As can be seen from these results, Klor-Con caused less drug-related GI toxicity than the comparative slow-release product, Slow-K, and no small or large bowel ulcers. The enteric-coated tablet did not produce the typical small bowel lesions usually seen with this product, although large intestinal lesions were observed. The reason for this may be that Enseals behaves more like a slow-release product, pharmacokinetically.

. . ..

Recommendation

This NDA would be recommended for approval.

.


-- --

---- -----

Burns, Janes 3/28/84

}

cc Orig. HFN-110 HFN-110/CS0 🛝 HFN-110/JPBurns sn/3/29/84/5601c



Upsher-Smith Labs. Minneapolis, MN Submission Date: July 31, 1985

Potassium Cl Klor-Con^R SR 600 mg tablets 750 mg tablets NDA # 19-123 Reviewer: Iyma Benedek

Review of a Bloequivalence Study

This submission has been reviewed by the Division of Biopharmaceutics and the study was rejected. The Division of Bioequivalence recommonds that the firm conduct a new bioequivalence study. Therefore, no further action is needed at this inme.

Junia Benedek, PhD.

Irma Benedek, Ph.D. Division of Bioequivalence Review Branch 3

RD INITIALED RMhatre M. M. ahe V Cam a bernt FT INITIALED RMhatre 11 5/85

IBenedek 10/29/85

cc: NDA # 19-123 original, HFN-230,(2) HFN-200 (Hare), HFN-223 (Shah - 2), HFN-258 (RMhatre, Benedek), Drug File